VALENCIA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its third quarter 2024 financial results after the close of the U.S. financial markets on Thursday, November 7, 2024. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 8, 2024, at 8:30 a.m. ...

I'm currently looking for an analyst position. If you like my articles, please shoot me a DM on here or add me on LinkedIn. Analyst's Disclosure: I/we have a beneficial long position in the shares of STXS, DCTH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I am conside ...

VALENCIA, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that management will participate in Lake Street Capital Markets' 8th Annual Best Ideas Growth (BIG8) Conference in New York on September 12, 2024. Jim Corbett, Chief Executive Officer, will host one-on-one meetings with institutional investors throughout the day. Fo ...

11 1 000 1 000 E 1 i r 1 E l L the state in er 1 t 1 t D-Keine Introduction AVITA Medical, Inc. (NASDAQ:RCEL) stock is down 47% since my last look in March. The title said it all: "Unconvincing Growth Amid Fierce Competition In The Burn Care Sector." My recommendation was hold, citing "unresolved concerns over S&M spending efficiency and competitive advantage." The company subscquently has released two earnings reports and launched RECELL GO, so let's take another look. AVITA Medical: Struggling to Balance ...

AVITA Medical, Inc. (NASDAQ:RCEL) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Joshua Jennings - TD Cowen Aaron Wukmir - Lake Street Capital Market Ross Osborne - Cantor Fitzgerald Lyanne Harrison - Bank of America Operator Good day and thank you for standing by. Welcome to the AVITA Medical Second Q ...

NASDAQ: RCEL ASX: AVH | --- | --- | --- | --- | --- | --- | |------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | Q2 2024 Earnings | | | | | | | Presentation | | | | | | | August 8, 2024 | | | | | | Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation and the accompanying oral commentary are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading SymbolName of each exchange on which registered Common Stock, par value $0.0001 per share RCEL The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

Exhibit 99.1 AVITA Medical Reports Second Quarter Financial Results VALENCIA, Calif., August 8, 2024 — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the second quarter ended June 30, 2024. Financial Results and Recent Business Updates • Commercial revenue of $15.1 million, an increase of approximately 29% compared to the same period in 2023 • ...

VALENCIA, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the second quarter ended June 30, 2024. Financial Results and Recent Business Updates Commercial revenue of $15.1 million, an increase of approximately 29% compared to the same period in 2023 Gross profit margin of 86.2% RECELL GO™ premarket appr ...

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc. VALENCIA, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Thursday, August 8, 2024. AVITA Medical will host a conference call and webcast ...